4D MOLECULAR THERAPEUTICS INC (FDMT)
Health Care · Gene therapy / AAV-based therapeutics for retinal and genetic diseases · NASDAQ
Gene therapy biotech advancing a durable, single-administration AAV treatment for wet AMD and diabetic macular edema with Phase 3 trials completing enrollment ahead of schedule.
What 4D MOLECULAR THERAPEUTICS INC does
4D Molecular Therapeutics is a late-stage biotechnology company developing durable, gene-therapy-based therapeutics targeting retinal vascular diseases and genetic lung diseases. Its lead program, 4D-150, utilizes a proprietary AAV vector platform to deliver anti-VEGF biologics and RNA interference for wet age-related macular degeneration and diabetic macular edema, with Phase 3 trials underway. The company is also advancing pipeline programs including 4D-175 for geographic atrophy, 4D-710 for cystic fibrosis lung disease, and 4D-725 for alpha-1 antitrypsin deficiency lung disease, primarily through strategic partnerships.
Themes: ["Gene therapy / AAV vectors","Retinal vascular diseases (wet AMD, DME)","Genetic lung diseases (CF, A1AT deficiency)","Anti-VEGF therapeutics","RNAi / RNA interference"]
Fundamentals
- Price$12.89 as of 2026-07-09 close
- Market cap$674M as of 2026-07-10
- 1-year return+208.5% as of 2026-07-09 close
- Net margin-182.3% as of 2026-07-10
- ROE-36.8% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+383560.9% as of 2026-07-10
- Revenue CAGR (3y)+200.9% SEC XBRL
- Beta2.69 as of 2026-07-10
Key risks (from latest filing)
["No approved products or product revenue; entirely dependent on successful development and regulatory approval of pipeline candidates, particularly 4D-150, with Phase 3 results not expected until 2027","Recurring net losses totaling $716.3 million accumulated deficit; continued significant cash burn expected with no near-term revenue generation; substantial capital requirements for ongoing clinical development and manufacturing scale-up","Gene therapy safety and manufacturing risks, including prior cases of intraocular inflammation in retinal programs and complexities in AAV vector manufacturing and commercial-scale production"]
Competitors & peers
- Regeneron Pharmaceuticals (REGN) — anti-VEGF biologics for retinal diseases
- Roche/Genentech — anti-VEGF and retinal disease therapeutics
- Novartis — retinal disease treatments and gene therapy programs
- Editas Medicine (NASDAQ: EDIT) — AAV-based gene therapy
- Regenxbio (NASDAQ: RGNX) — AAV gene therapy platform
- AABB (acquired; formerly Applied Genetic Technologies) — retinal gene therapy
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.